Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study
-
- Tomoki Kimura
- Department of Radiation Oncology Hiroshima University Hospital Hiroshima Hiroshima Japan
-
- Atsuya Takeda
- Radiation Oncology Center Ofuna Chuo Hospital Kamakura Kanagawa Japan
-
- Naoko Sanuki
- Radiation Oncology Center Ofuna Chuo Hospital Kamakura Kanagawa Japan
-
- Keisuke Ariyoshi
- Department of Data Management JORTC Data Center Arakawa‐ku Tokyo Japan
-
- Takuhiro Yamaguchi
- Division of Biostatistics Tohoku University Graduate School of Medicine Sendai Miyagi Japan
-
- Toshiyuki Imagumbai
- Department of Radiation Oncology Kobe City Medical Center General Hospital Kobe Hyogo Japan
-
- Norio Katoh
- Department of Radiation Oncology Faculty of Medicine Hokkaido University Sapporo Hokkaido Japan
-
- Takahisa Eriguchi
- Department of Radiation Oncology Saiseikai Yokohamashi Tobu Hospital Yokohama Kanagawa Japan
-
- Yohei Oku
- Radiation Oncology Center Ofuna Chuo Hospital Kamakura Kanagawa Japan
-
- Shuichi Ozawa
- Department of Radiation Oncology Hiroshima University Hospital Hiroshima Hiroshima Japan
-
- Yuichiro Tsurugai
- Radiation Oncology Center Ofuna Chuo Hospital Kamakura Kanagawa Japan
-
- Masaki Kokubo
- Department of Radiation Oncology Kobe City Medical Center General Hospital Kobe Hyogo Japan
-
- Shinichi Shimizu
- Department of Radiation Medical Science and Engineering Faculty of Medicine Hokkaido University Sapporo Hokkaido Japan
-
- Satoshi Ishikura
- Department of Radiology Nagoya City University Graduate School of Medical Sciences Nagoya Aichi Japan
この論文をさがす
抄録
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>To prospectively evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for patients with previously untreated solitary primary hepatocellular carcinoma (HCC).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The main eligibility criteria included the following: (1) primary solitary HCC; (2) no prior treatment for HCC; (3) Child–Turcotte–Pugh score of seven or less; and (4) unsuitability for or refusal of surgery and radiofrequency ablation (RFA). The prescribed dose of SBRT was 40 Gy in five fractions. The primary endpoint was 3‐year overall survival (OS); the secondary endpoints included local progression‐free survival (LPFS), local control (LC), and adverse events. The accrual target was 60 patients, expecting a 3‐year OS of 70% with a 50% threshold.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Between 2014 and 2018, 36 patients were enrolled; enrollment was closed early because of slow accrual. The median tumor size was 2.3 cm. The median follow‐up at the time of evaluation was 20.8 months. The 3‐year OS was 78% (95% confidence interval [CI]: 53%–90%). The 3‐year LPFS and LC proportion were 73% (95% CI: 48%–87%) and 90% (95% CI: 65%–97%), respectively. Grade 3 or higher SBRT‐related toxicities were observed in four patients (11%), and grade five toxicities were not observed.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This study showed acceptably low incidence of SBRT‐related toxicities. LC and OS after SBRT were comparable for previously untreated solitary HCC for patients unfit for resection and RFA. Although a definitive conclusion cannot be drawn by this study, the promising results indicate that SBRT may be an alternative option in the management of early HCC.</jats:p></jats:sec>
収録刊行物
-
- Hepatology Research
-
Hepatology Research 51 (4), 461-471, 2021-03
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360009142595497088
-
- ISSN
- 1872034X
- 13866346
-
- データソース種別
-
- Crossref
- KAKEN